Market Overview

UPDATE: Citigroup Downgrades Edwards Lifesciences Corp. to Neutral, Lowers PT

Share:
Related EW
JPMorgan: Time To Buy Edwards Lifesciences
Oppenheimer: 3 Healthcare Stocks And 2 Energy Stocks To Buy Now
4 Can't Miss Industry Trends With High Growth Potential (Seeking Alpha)

In a report published Friday, Citigroup downgraded its rating on Edwards Lifesciences Corp. (NYSE: EW) from Buy to Neutral, and lowered its price target from $101.00 to $95.00.

Citigroup noted, “We rate Edwards Lifesciences (EW) Neutral. The near term ramp in US TAVI will likely take longer to materialize than originally expected despite recent approval of Cohort A, and combined with the macro issues in Europe that continue to add uncertainty to the global TAVI market, we believe visibility on the near-term market opportunity is limited despite believing that the longer-term opportunity remains intact.”

Edwards Lifesciences Corp. closed on Thursday at $86.14.

Latest Ratings for EW

DateFirmActionFromTo
May 2015JP MorganUpgradesNeutralOverweight
Apr 2015BarclaysMaintainsEqual-weight
Dec 2014BarclaysMaintainsEqual-weight

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Downgrades Analyst Ratings

 

Related Articles (EW)

Around the Web, We're Loving...

Get Benzinga's Newsletters